Trial Profile
A study of cardiopulmonary exercise testing (CPET) to evaluate the clinical status associated with either the addition of macitentan to sildenafil monotherapy or the switch from bosentan to macitentan in patients with pulmonary arterial hypertension
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Macitentan (Primary) ; Sildenafil
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2017 New trial record
- 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society